US20130237512A1 - Stabilizing compositions for antibiotics and methods of use - Google Patents
Stabilizing compositions for antibiotics and methods of use Download PDFInfo
- Publication number
- US20130237512A1 US20130237512A1 US13/873,391 US201313873391A US2013237512A1 US 20130237512 A1 US20130237512 A1 US 20130237512A1 US 201313873391 A US201313873391 A US 201313873391A US 2013237512 A1 US2013237512 A1 US 2013237512A1
- Authority
- US
- United States
- Prior art keywords
- composition
- present
- silicon dioxide
- medium chain
- triglycerides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 199
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 28
- 238000000034 method Methods 0.000 title description 25
- 229940088710 antibiotic agent Drugs 0.000 title description 12
- 230000000087 stabilizing effect Effects 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 42
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 39
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical group OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 33
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 32
- 239000003781 beta lactamase inhibitor Substances 0.000 claims description 30
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims description 30
- 229960003324 clavulanic acid Drugs 0.000 claims description 26
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- 235000012239 silicon dioxide Nutrition 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 17
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 7
- 239000000391 magnesium silicate Substances 0.000 claims description 7
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 7
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 7
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 7
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 4
- 229960005256 sulbactam Drugs 0.000 claims description 4
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 4
- 229960003865 tazobactam Drugs 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 56
- 238000009472 formulation Methods 0.000 abstract description 54
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 53
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 45
- 229960003022 amoxicillin Drugs 0.000 description 40
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 40
- 229930182555 Penicillin Natural products 0.000 description 27
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 102000006635 beta-lactamase Human genes 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 150000002960 penicillins Chemical class 0.000 description 14
- 229940049954 penicillin Drugs 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000012053 oil suspension Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000002132 β-lactam antibiotic Substances 0.000 description 10
- 229940124586 β-lactam antibiotics Drugs 0.000 description 10
- 108020004256 Beta-lactamase Proteins 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical group [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 8
- 229940124587 cephalosporin Drugs 0.000 description 8
- 150000001780 cephalosporins Chemical class 0.000 description 8
- 229920001903 high density polyethylene Polymers 0.000 description 8
- 239000004700 high-density polyethylene Substances 0.000 description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 description 7
- 229940090805 clavulanate Drugs 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010033078 Otitis media Diseases 0.000 description 6
- 229940098164 augmentin Drugs 0.000 description 6
- -1 dicloacllin Chemical compound 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 5
- 229960003669 carbenicillin Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 5
- 108010087702 Penicillinase Proteins 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960004920 amoxicillin trihydrate Drugs 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 229940056360 penicillin g Drugs 0.000 description 4
- 229950009506 penicillinase Drugs 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 4
- 229960004659 ticarcillin Drugs 0.000 description 4
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 229930195708 Penicillin V Natural products 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960003326 cloxacillin Drugs 0.000 description 3
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 3
- 229960000515 nafcillin Drugs 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 125000003835 nucleoside group Chemical class 0.000 description 3
- 125000003729 nucleotide group Chemical class 0.000 description 3
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 3
- 229960001019 oxacillin Drugs 0.000 description 3
- 229940056367 penicillin v Drugs 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 3
- 229960002292 piperacillin Drugs 0.000 description 3
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical group CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 125000003460 beta-lactamyl group Chemical group 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 229940041011 carbapenems Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960000717 carindacillin Drugs 0.000 description 2
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- 229960003012 cefamandole Drugs 0.000 description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- 229960004489 cefonicid Drugs 0.000 description 2
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 2
- 229960004682 cefoperazone Drugs 0.000 description 2
- 229960005495 cefotetan Drugs 0.000 description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 229960002620 cefuroxime axetil Drugs 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 2
- 229960001585 dicloxacillin Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229960001977 loracarbef Drugs 0.000 description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 229960000198 mezlocillin Drugs 0.000 description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 2
- 239000002773 nucleotide Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229950000033 proxetil Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000007966 viscous suspension Substances 0.000 description 2
- OPEGYZAATHKDEM-HCWXCVPCSA-N (2r,4s)-2-[(r)-carboxy(formamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid Chemical compound CC1(C)S[C@H]([C@H](NC=O)C(O)=O)N[C@H]1C(O)=O OPEGYZAATHKDEM-HCWXCVPCSA-N 0.000 description 1
- UBEIMDKGOYBUKT-FLIQGJDUSA-N 1,2,3-trilinolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC UBEIMDKGOYBUKT-FLIQGJDUSA-N 0.000 description 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- MBXVIRZWSHICAV-UHFFFAOYSA-N Glycerol triundecanoate Chemical compound CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCC)COC(=O)CCCCCCCCCC MBXVIRZWSHICAV-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940086793 amoxicillin 250 mg Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000003303 sex hormone antagonist Substances 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940027257 timentin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is directed to improved liquid antibiotic formulations.
- the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- ⁇ -Lactam antibiotics are commonly prescribed antibiotics that are active against both gram-positive and gram-negative organisms. See Goodman and Gilman's, The Pharmacological Basis of Therapeutics, Ninth Ed., 1996 (Goodman and Gilman's). Penicillins include penicillins G and V which are active against gram-positive cocci, naficillin which is active against penicillinase-producing Staphylococcus aureus and ampicillin which has an improved gram-negative spectrum of activity. Unfortunately, bacterial resistance to ⁇ -lactam antibiotics is growing. A major mechanism of resistance involves the production of ⁇ -lactamases by the bacteria. ⁇ -lactamases cleave the ⁇ -lactam ring generating penicilloic acid, which is not bacteriocidal.
- ⁇ -lactamases can be inhibited by molecules which bind to the ⁇ -lactamases, acting as competitive substrates for the enzymes.
- One such molecule, clavulanic acid binds irreversibly to the ⁇ -lactamases, irreversibly inhibiting the enzyme.
- the addition of ⁇ -lactamase inhibitors to penicillins is very important because it extends the spectrum of bacteriocidal activity.
- the combination of amoxicillin and clavulanic acid is effective against the ⁇ -lactamase-producing strains of staphylococci, H. influenza , gonococci and E. coli .
- clavulanic acid to ticarcillin extends its bacteriocidal activity to include aerobic gram-negative bacilli, Staphylococcus aureus as well as Bacteroides species.
- Other ⁇ -lactamases inhibitors include, sulbactam and tazobactam.
- ⁇ -lactamase inhibitors such as clavulanic acid are unstable in aqueous media.
- Clavulanic acid is susceptible to hydrolytic degradation. There exists a narrow range of pH and temperature where the molecule is most stable. Wildfeuer et al. Arzneistoffforschung 41(1):70-73 (1991).
- the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- the antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a carbapenem, and mixtures thereof.
- the antibiotic is a penicillin selected from the group consisting of penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloacllin, ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, meziocillin, aziocillin, and mixtures thereof.
- the triglycerides can be selected from the group consisting of short chain triglycerides, medium chain triglycerides, and long chain triglycerides. In some embodiments, the triglycerides are medium chain triglycerides.
- the triglycerides can be about 5% (w/v) to about 99% (w/v), about 25% (w/v) to about 99% (w/v), about 50% (w/v) to about 99% (w/v), about 75% (w/v) to about 99% (w/v), about 85% (w/v) to about 99% (w/v), or about 95% (w/v) to about 99% (w/v) of the composition.
- the composition has less than about 1% water (w/v), in another embodiment there is less than about 0.5% water (w/v), and in a third embodiment there is less than about 0.1% water (w/v).
- the composition can also be a dry triglyceride liquid formulation in some embodiments.
- composition of the present invention can further comprise a ⁇ -lactamase inhibitor, for example, clavulanic acid.
- a ⁇ -lactamase inhibitor for example, clavulanic acid.
- the compositions of the present invention comprise clavulanic acid, amoxicillin, and medium chain triglycerides.
- the present invention is further directed to a composition
- a composition comprising a penicillin and a ⁇ -lactamase inhibitor in a liquid comprising medium chain triglycerides, wherein the concentration of triglycerides ranges from about 5% (w/v) to about 95% (w/v), and wherein the composition has less than about 5% water (w/v).
- the penicillin is amoxicillin and the ⁇ -lactamase inhibitor is clavulanic acid.
- the concentration of amoxicillin ranges from about 50 mg/5 ml to about 800 mg/5 ml and clavulanic acid ranges from about 10 mg/5 ml to about 80 mg/5 ml.
- the present invention is also directed to a composition
- a composition comprising a penicillin and a ⁇ -lactamase inhibitor, wherein the penicillin and ⁇ -lactamase inhibitor are in a liquid comprising medium chain triglycerides, wherein the concentration of triglycerides can be about 70% (w/v) to about 99% (w/v).
- the penicillin or antibiotic is stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C.
- kits comprising any embodiment of the compositions of the present invention.
- the present invention is directed to a kit comprising a composition comprising an antibiotic which can be mixed with a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- the kit comprises (a) a first container comprising a therapeutically effective amount of an antibiotic and (b) a second container comprising a pharmaceutically acceptable carrier, excipient, diluent or combination thereof.
- at least one container can be made of high density polyethylene.
- the present invention is also directed to methods of using the compositions of the present invention.
- the present invention is directed to a method of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v) to the mammal in need thereof.
- FIG. 1 illustrates exemplary embodiments of the present invention.
- the present invention is directed to compositions comprising an antibiotic compound in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- the composition can further comprise a ⁇ -lactamase inhibitor.
- the antibiotic compound can be in suspension or in solution in the liquid comprising triglycerides.
- antibiotic encompasses any pharmaceutically acceptable compound that can inhibit the growth of or destroy bacteria and/or other microbes, regardless of whether the compound is produced in a microorganism or produced synthetically. This term encompasses disinfectants, antiseptics, and any other antimicrobial compounds. For example, the term “antibiotic” encompasses penicillin and all its derivatives.
- Suitable antibiotics for use in the present invention include, but are not limited to, the ⁇ -lactam class of antibiotics which comprises penicillins, cephalosporins, and carbapenems.
- ⁇ -lactam antibiotics are useful as antimicrobial agents. These compounds inhibit the synthesis of the bacterial peptidoglycan cell wall and are active against both gram-positive and gram-negative cell walls.
- Penicillins can be generally classified based on their spectrum of microbial activity. Penicillin G and penicillin V are highly active against strains of gram-positive cocci. However, these drugs are readily hydrolyzed by penicillinase making them ineffective against most strains of Staphylococcus aureus .
- the antibiotic of the present invention is penicillin G, penicillin V, or a mixture thereof.
- Penicillinase-resistant penicillins tend to have less potent antimicrobial activity against microbes sensitive to penicillin G but these penicillins are active against Staphylococcus aureus .
- Exemplary penicillinase-resistant penicillins include, but are not limited to, methicillin, nafcillin, oxacillin, cloxacillin, and dicloxacillin.
- the antibiotic of the present invention is methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, or a mixture thereof.
- penicillins include those whose spectrum of antimicrobial activity extends to include gram-negative organisms such as Haemophilus influenza, E. coli , and Proteus mirabilis . However, these drugs are hydrolyzed by ⁇ -lactamases that are found in increasing numbers of gram-negative bacteria.
- the antibiotic of the present invention is ampicillin, amoxicillin, bacampicillin, or a mixture thereof.
- penicillins such as, carbenicillin, carbenicillin indanyl, and ticarcillin are classified together because their spectrum of antimicrobial activity includes Pseudomonas, Enterobacter , and Proteus species.
- Other extended-spectrum penicillins include mezlocillin and piperacillin, which have activity against Pseudomonas, Klebsiella , and other gram-negative microbes.
- these drugs are also hydrolyzed by ⁇ -lactamases.
- the antibiotic of the present invention is carbenicillin, carbenicillin indanyl, ticarcillin, mezlocillin, piperacillin, or a mixture thereof.
- cephalosporins can be categorized depending on their generation, as described in Goodman and Gilman's.
- First generation cephalosporins include cephalothin, cefazolin, cephalexin, and cefadroxil.
- Second generation cephalosporins include cefamandole, cefoxitin, cefaclor, cefuroxime, cefuroxime axetil, loracarbef, cefonicid, cefotetan, and ceforamide.
- Third generation cephalosporins include cefoxatime, cefopodoxime proxetil, cefizoxime, cefoperazone, and ceftazidime.
- an exemplary fourth generation cephalosporin is cefepime.
- the antibiotic of the present invention is cephalothin, cefazolin, cephalexin, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefuroxime axetil, loracarbef, cefonicid, cefotetan, ceforamide, cefoxatime, cefopodoxime proxetil, cefizoxime, cefoperazone, ceftazidime, cefepime, or a mixture thereof.
- the present invention is further directed to using ⁇ -lactam antibiotics other than penicillins or cephalosporins.
- These other ⁇ -lactam antibiotics include those compounds that have a ⁇ -lactam structure but are not considered a penicillin or cephalosporin.
- the carbapenems which include imipenem, meropenem, and aztreonam.
- the antibiotic of the present invention is imipenem, meropenem, aztreonam, or a mixture thereof.
- the above list of antibiotics is not exhaustive and other antibiotics which are not mentioned are also encompassed within the present invention.
- the compositions of the present invention can comprise more than one antibiotic.
- the present invention is also directed to a composition comprising more than one antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- the present invention comprises 2, 3, 4, or 5 or more antibiotics in combination.
- the antibiotics used in the embodiments of the present invention that comprise more than one antibiotic can be selected from a group consisting of, but not limited to, a penicillin, a cephalosporin, a carbapenem, or a mixture thereof.
- the embodiments of the present invention that include more than one antibiotic can be useful for treating mammals with an infection from more than one bacteria or other microbe.
- a physician may prescribe a penicillin such as carbenicillin to treat an infection caused by Pseudomonas and a second antibiotic to treat an infection caused by a different microbe that carbenicillin cannot treat.
- ⁇ -lactam antibiotics are susceptible to inactivation by ⁇ -lactamase.
- the ⁇ -lactamase enzyme opens the ⁇ -lactam ring in penicillin or other ⁇ -lactam antibiotics. This change produces penicillonic acid (from penicillins) and eliminates the antibiotic properties of penicillin. Similar attacks reduce the ability of other ⁇ -lactam antibiotics to treat microbe caused diseases. See Despande et. al, Degradation of ⁇ -lactam Antibiotics, Current Science, 87:12 1684-1695 (2004).
- ⁇ -lactamase inhibitor is a compound that can bind ⁇ -lactamase thereby preventing it from inactivating the antibiotic.
- this term encompasses all forms of the compound including, for example, acids, bases, salts, and esters thereof, as well as polymorph crystal forms.
- a “ ⁇ -lactamase inhibitor” refers to a pharmaceutically acceptable salts selected from, but not limited to, alkali metal salts such as sodium or potassium, alkaline earth salts or an ammonium salt (all of which are herein referred to as a pharmaceutically acceptable salts).
- compositions of the present invention further comprise a ⁇ -lactamase inhibitor.
- the ⁇ -lactamase inhibitor can be clavulanic acid, sulbactam, tazobactam, or mixtures thereof, as well as the salts and esters of these compounds.
- the ⁇ -lactamase inhibitor is potassium clavulanate.
- ⁇ -lactamase inhibitors are often prescribed in association with amino- and ureidopenicillins for treating gram-negative infections. See Naas et al., Integration of a Transposon TnI-Encoded Inhibitor-Resistant ⁇ -Lactamase Gene, bla TEM-67 from Proteus mirabilis , into the Escherichia coli Chromosome, Antimicrobial Agents and Chemotherapy, 47:1 p. 19-26, (2003).
- clavulanic acid has been combined with amoxicillin to form an oral preparation (AUGMENTIN®, available from GlaxoSmithKline, Research Triangle Park, N.C.) and with tiarcillin as a parenteral preparation (TIMENTIN®, available from GlaxoSmithKline, Research Triangle Park, N.C.).
- oral preparation available from GlaxoSmithKline, Research Triangle Park, N.C.
- TIMENTIN® available from GlaxoSmithKline, Research Triangle Park, N.C.
- the mixture when amoxicillin and clavulanic acid are used together, the mixture can be reconstituted in water before it is administered to a patient. Even when stored at 4° C., the clavulanic acid degrades rapidly, reducing its effectiveness.
- compositions of the present invention comprise less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% water (w/v).
- the present invention can also comprise less than 5%, 4%, 3%, 2%, 1%, 0.1%, 0.01% (w/v) or be completely free of water.
- These low water embodiments can be used with water labile components, for example, clavulanic acid.
- triglycerides to a liquid suspension containing an antibiotic, e.g. a ⁇ -lactam, and a ⁇ -lactamase inhibitor, e.g. clavulanic acid, prevents degradation of the clavulanic acid.
- an antibiotic e.g. a ⁇ -lactam
- a ⁇ -lactamase inhibitor e.g. clavulanic acid
- Triglycerides also known as triacylglycerol or triacylglyceride
- Triglycerides are glycerides in which the glycerol is esterified with three fatty acids. Triglycerides are the main constituent of vegetable oil and animal fats. The general chemical structure of triglycerides is shown below:
- R′, R′′, and R′′′ are alkyl chains (C 1 -C n ).
- Chain lengths of the fatty acids in naturally occurring triglycerides may range from 3 to 24 carbon atoms, but lengths of 16 and 18 carbon atoms are most common. Shorter chain lengths may be found in some substances (butyric acid in butter). Most naturally occurring fats contain a complex mixture of individual triglycerides. Based on their chain length, triglycerides can be divided into three categories: (i) short chain triglycerides (SCT); (ii) medium chain triglycerides (MCT); and (iii) long chain triglycerides (LCT).
- SCT short chain triglycerides
- MCT medium chain triglycerides
- LCT long chain triglycerides
- Short chain triglycerides are triglycerides having short chain fatty acids, e.g., C 2 -C 6 .
- one short chain triglyceride is glyceryl tributyrate.
- Medium chain triglycerides have fatty acids ranging from about C 8 to about C 10 .
- Some exemplary commercially available medium chain triglycerides are LABRAFAC® (available from Gattefossé Pharma, Saint-Priest Cedex, France) CAPTEX® (available from Parchem, White Plains, N.Y.), NESATOL® (available from Kreglinger Europe, Antwerp, Belgium) WAGLINOL® (available from Industrial Quimica Lasem, S.
- BERGABEST® available from Sternchemie, Hamburg, Germany
- MIGLYOL® available from Universal Preserv-A-Chem, Inc., Edison, N.J.
- NEOBEE® available from Stepan Company, Northfield, Ill.
- CRODAMOL® available from Croda, Edison, N.J.
- Triglycerides longer than a medium chain triglyceride, e.g. C 11 to C x are called long chain triglycerides.
- One exemplary long chain triglyceride is castor oil.
- compositions of the present invention can comprise a short chain, medium chain, or long chain triglyceride.
- the triglyceride is a medium chain triglyceride.
- the use of a medium chain triglyceride can increase the bioavailability of a drug. See Ueda et al., Effect of Ethyl Cellulose in a Medium-Chain Triglyceride on the Bioavailability of Ceftizoxime, J Pharm Sci. 72(4):454-8 (1983).
- the present invention can also comprise a mixture of triglycerides.
- the mixture of triglycerides comprises a mixture of a short chain and a medium chain, a short chain and a long chain, or a medium chain and a long chain. Further, the mixture of triglycerides can comprise more than one short chain, more than one medium chain, or more than one long chain.
- compositions of the present invention can comprise about 1% to about 99% triglycerides (w/v).
- the inactive components of the present invention comprise about 1% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to about 100% triglycerides (w/v).
- the composition comprises about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of triglycerides (w/v).
- the term “about” refers to plus or minus 10% of the indicated number. For example, “about 10%” indicates a range of 9% to 11%.
- the triglycerides are selected from the group consisting of, but not limited to, vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, modified triglycerides, fractionated triglycerides, medium and long-chain triglycerides, structured triglycerides, and mixtures thereof.
- the triglycerides can be almond oil; babassu oil; borage oil; blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil; evening primrose oil; grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil; sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate; glyceryl
- compositions of the present invention can further comprise stabilizing agents.
- a “stabilizing agent” is a compound that can prevent or slow the degradation of the antibiotic or ⁇ -lactamase inhibitor while in storage.
- compositions of the present invention are stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C. In some embodiments, the compositions of the present invention are stable for about ten days to about 31 days when stored at a temperature of about 20° C. to about 25° C.
- compositions of the present invention are stable at a temperature of about 20° C. to about 25° C. during a course of antibiotic treatment.
- the compositions of the present invention do not require refrigeration during a course of antibiotic treatment.
- a course of antibiotic treatment can be, but is not limited to, about 1, about 3, about 5, about 7, about 10 days, or about 31 days.
- a course of antibiotic treatment can be as long as the antibiotics are prescribed for use by a medical professional authorized to prescribe antibiotics. This can length can be determined based on the needs and characteristics of the individual patient. For example, if the patient is immunosuppressed or immunocompromised then the course of antibiotic treatment can be longer than a week, a month, or a year, depending on the patient's condition.
- the present invention can further comprise a pharmaceutically acceptable excipient other than the triglycerides previously mentioned.
- An “excipient” refers to a substance that is used in the formulation of pharmaceutical compositions, and, by itself, generally has little or no therapeutic value.
- Various excipients can be used in the invention, including those described in Remington: The Science and Practice of Pharmacy, 21 st Ed. (2006). Excipients include, but are not limited to, antioxidants, anti-bacterial agents that prevent the decay of the formulation itself as opposed to those exhibiting a therapeutic effect, preservatives, chelating agents, buffering agents, agents for adjusting toxicity, colorings, flavorings and diluting agents, emulsifying and suspending agents, and other substances with pharmaceutical applications.
- pharmaceutically acceptable excipient refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized international pharmacopoeia for use in animals, and more particularly in humans.
- the excipients used in the compositions of the present invention are pharmaceutically acceptable.
- At least one of the excipients included in the liquid formulation can be further dried to reduce its moisture content.
- the formulation uses dried silicon dioxide, colloidal silicon dioxide, magnesium trisilicate, or combinations of these excipients. The drying can be done using any method known to one of skill in the art, for example, by placing the excipient in a 105° C. oven overnight.
- the dried excipients can be combined with low moisture content medium chain triglycerides (e.g., a moisture content of about 0.0275% w/w).
- low moisture content medium chain triglycerides e.g., a moisture content of about 0.0275% w/w.
- dried silicon dioxide, dried colloidal silicon dioxide and dried magnesium trisilicate and low moisture medium chain triglyceride oil e.g. 0.0275%, w/w
- an active ingredient such as an antibiotic.
- Some embodiments of the present invention are directed to dry or dehydrated triglyceride liquid formulations comprising an antibiotic.
- dry triglyceride liquid formulations or “dehydrated triglyceride liquid formulations” both refer to pharmaceutical formulations comprising a triglyceride that are substantially free, and in some cases totally free, of water, and can be considered to be dehydrated. These formulations can also be considered anhydrous.
- Such formulations can be prepared using low moisture content medium chain triglycerides and powdered excipients with low moisture contents. The powdered excipients can be further dried to reduce their moisture content.
- dry is used in relation to a liquid to mean that the liquid and its contents have a low or a reduced water content. This use of the term “dry” is not intended to mean the liquid is devoid of fluid-like characteristics, e.g., it has become a powder.
- the dry triglyceride liquid formulations of present invention are particularly useful in preventing hydrolytic degradation of clauvanic acid and/or potassium clauvanate when they are in a reconstituted antibiotic formulation. While not wishing to be bound to a single theory, the drying or desiccation of the excipients is believed to maximize their hygroscopic behavior in the reconstituted formulation.
- silicon dioxide is very hygroscopic and adsorbs large quantities of water up to 30% (w/w) with a relative humidity of around 80% (w/w). This adsorbtive ability is impaired if the silicon dioxide is exposed to humidity or other water before it becomes part of the reconstituted formulation. However, in its dried form, it is believed to adsorb water from within the formulation, which reduces the hydrolytic degradation of clauvanic acid and/or potassium clauvanate when they are in a reconstituted antibiotic formulation.
- compositions of the present invention can be administered to any mammal in need of the composition that can experience the beneficial effects of the compounds of the invention.
- mammals include humans and non-humans, such as pets and farm animals.
- the present invention is directed to methods of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v), to the mammal in need thereof.
- the patient is a child. In some embodiments, the patient is about 55 years of age or older. In some embodiments, the patient has a bacterial infection. In some embodiments, the patient has a condition that compromises their immune system, e.g., AIDS or advanced stage cancer.
- the dosage of the antibiotic administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, the frequency of treatment, and the nature of the effect desired.
- the compositions of the present invention can contain a quantity of a compound(s) according to this invention in an amount effective to treat the condition, disorder or disease of the subject being treated.
- a method of administering pharmaceutically effective amounts of the antibiotic to a patient in need thereof can be determined empirically, or by standards currently recognized in the medical arts. It will be understood that, when administered to, for example, a human patient, the total daily dosage of the agents of the compositions of the present invention will be decided within the scope of sound medical judgment by the attending physician.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, gender and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the agents at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.
- compositions of the present invention can be administered in combination with another therapeutic agent.
- the compositions of the present invention can also include one or more additional therapeutic agents such as, but not limited to, hydrophilic drugs, hydrophobic drugs, hydrophilic macromolecules, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, antibodies, vaccines, nucleosides, nucleotides, nucleoside analogs, genetic materials and/or combinations thereof.
- therapeutic agents that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, other antineoplastic agents, analgesics and anti-inflammatory agents, anti-anginal agents, antihelmintics, anti-arrythmic agents, anti-arthritic agents, anti-asthma agents, anti-viral agents, anti-coagulants, anti-depressants, antidiabetic agents, anti-epileptic agents, anti-emetics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarial agents, antimigraine agents, anti-muscarinic agents, anti-Parkinson's agents, anti-protozoal agents, anti-thyroid agents, thyroid therapeutic agents, anti-tussives, anxiolytic agents, hypnotic agents, neuroleptic agents, beta-blockers, cardiac inotropic agents, corticosteroids, diuretics, gastrointestinal agents, histamine H 2 -receptors antagonists, immunosuppressants
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of extent of condition, disorder or disease; stabilization (i.e., not worsening) of the state of condition, disorder or disease; delay in onset or slowing of condition, disorder or disease progression; amelioration of the condition, disorder or disease state, remission (whether partial or total), whether detectable or undetectable; or enhancement or improvement of condition, disorder or disease.
- Treatment includes eliciting a clinically significant response, without excessive levels of side effects.
- Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
- the present invention is directed to a method of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, to the mammal in need thereof.
- a “pharmaceutically effective amount” means an amount effective to provide a therapeutic effect during a period of treatment.
- the effect can be the treatment of a bacterial infection or other microbe-caused disease state or condition.
- the present infection is directed to a pharmaceutically effective amount of an antibiotic is administered to a mammal in need thereof.
- the methods and compositions of the present invention can be used to treat microbial caused diseases.
- the methods and compositions of the present invention can be used to treat otitis media.
- Otitis media is an infection or inflammation of the middle ear caused by viral or bacterial infections. It is estimated that 75% of children experience at least one episode of otitis media by their third birthday, however, this infection is not limited to children.
- Otitis media can be treated using antibiotics.
- compositions of the present invention can be administered to a patient with otitis media to treat the infection.
- kits comprising a composition of the present invention.
- the kits of the present invention further comprise a container or other means for holding the compositions of the present invention.
- aqueous based antibiotic formulations can be prepared at the pharmacy by mixing a measured amount of the powdered components with water. These formulations require refrigeration after mixing.
- kits of the present invention can be used to prepare the pharmaceutical compositions in a manner distinct from traditional kits.
- the medium chain triglycerides can be in a container separate from the powdered components, which can be in their own distinct container.
- the powdered components can comprise an antibiotic and clavulanic acid, or another ⁇ -lactamase inhibitor, either together or in separate containers. This allows the pharmacist to either pour the powders into the container with the liquid or vice versa. Storing the liquid and powder components in separate containers within a kit helps keep all the formulary components moisture-free because each container is only opened at the time of reconstitution, limiting the exposure to moisture in the environment.
- the kit comprises (a) a first container or other means for containing a therapeutically effective amount of the composition of the present invention and (b) a second container or other means for containing a pharmaceutically acceptable carrier, excipient, diluent or combination thereof.
- a pharmaceutically acceptable carrier for example, the powdered portion of the formulation is stored in one container while the liquid is stored in a separate container.
- the kit can have additional containers or other means for containing comprising a therapeutically effective amount of additional agents or excipients.
- the kit comprises a container or other means for containing for the separate compositions, such as, a divided bottle or a divided foil packet, however, the separate compositions can also be contained within a single, undivided container.
- the kit contains directions for administration of the separate components.
- the kit form is particularly advantageous when the separate components are preferably administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
- the antibiotic is in one container or other means for containing and the triglycerides are in another.
- the physician or pharmacist can then mix the two components to form a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- Any powdered excipients desired for the formulation can be present with the triglycerides (e.g., in a solution or a suspension) or they can be in a mixture with the antibiotic.
- the ⁇ -lactamase inhibitor may be in a container with the antibiotic or separate from the antibiotic in another container with powder.
- the kit of the present invention can further comprise an additional container or means for containing comprising a therapeutically effective amount of an agent selected from the group consisting of hydrophilic drugs, hydrophobic drugs, hydrophilic macromolecules, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, antibodies, vaccines, nucleosides, nucleotides, nucleoside and/or nucleotide analogs, genetic materials and combinations thereof.
- an agent selected from the group consisting of hydrophilic drugs, hydrophobic drugs, hydrophilic macromolecules, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, antibodies, vaccines, nucleosides, nucleotides, nucleoside and/or nucleotide analogs, genetic materials and combinations thereof.
- the container or other means for containing of the kit is a bottle.
- This bottle can be moisture-proof, including a moisture proof cap. It is also important to select a bottle that will not be permeable to the triglycerides of the present invention, in particular, to the medium chain triglycerides. Some polymers that are suitable for aqueous solutions would not be suitable for use in the kits of the present invention.
- Suitable containers or other means for containing include, but are not limited to, bottles made of high density polyethylene (HDPE), polypropylene (PP), glass, and metal.
- HDPE bottles are particularly suited for the present invention because molecules of HDPE have fewer branches and side chains which leads to higher density and smaller pores. This makes it an effective barrier to contain medium chain triglycerides within the bottle as well as an effective barrier to prevent an influx of water.
- the container is a HDPE bottle.
- the container is not limited to HDPE bottles.
- Table 1 shows a comparison of the properties of some more bottles contemplated for use in the present invention.
- a method according to the present invention comprises preparing a pharmaceutical composition by combining a dehydrated triglyceride with a powdered antibiotic and, optionally, a ⁇ -lactamase inhibitor such as clavulanic acid. Any of the kits of the present invention are useful in this method.
- compositions of the present invention have better stability than aqueous solutions containing clavulanic acid.
- samples of some embodiments of the present invention are prepared at potassium clavulanate concentrations of 15 mg/5 mL, 35 mg/5 mL and 90 mg/5 mL. Each sample is dispersed in a vehicle of medium chain triglycerides and water. Further, the above sample preparation is repeated with the addition of amoxicillin at 250 mg/5 mL.
- Table 2 shows the ratios of MCT:water that are used in each sample prepared.
- the pH of the samples is controlled so that the mixture of amoxicillin and potassium clavulanate have a pH of about 3.8 to about 6.6.
- Solutions of pure amoxicillin (2 mg/ml) have an optimum pH range of about 3.8 to about 6.0 and solutions of pure clavulanate potassium (1% solution) have an optimum pH range of about 3.8 to about 8.0.
- samples are stored at both a temperature of about 20° C. to about 25° C. and under refrigeration (about 4° C.) and are tested for pH and the amount of amoxicillin and clavulanate.
- the pH is measured using any technique known to one of skill in the art. For example, using the methods described in the U.S. Pharmacopoeia.
- the amount of amoxicillin and clavulanate are measured using HPLC or other assay capable of measuring the amount of amoxicillin and clavulanate. Quantification of the compounds by HPLC is used to determine the unknown concentration of both amoxicillin and clavulanate in the samples.
- the samples are injected (about 10-20 ⁇ l) into a liquid chromatograph equipped with a 210-nm detector and a 4-mm ⁇ 30-cm column that contains 3- to 10- ⁇ m packing L1. See U.S. Pharmacopoeia.
- the peaks of the sample are compared to the injection of a series of known concentrations of the standard compound solution (e.g., about 10 ⁇ l of amoxicillin and/or about 20 ⁇ l of clavulanate) onto the HPLC for detection.
- the chromatograph of these known concentrations gives a series of peaks that correlate to the concentration of the samples that are injected.
- the chromatogram is recorded and the responses for the major peaks are measured.
- One of skill in the art can then determine the percentage of clavulanate or amoxicillin in the solution using the methods described in the U.S. Pharmacopoeia or other equivalent method.
- the stability of the composition can be tested using methods other than HPLC.
- bioassays and spectrophotometric methods could be used in place of HPLC or in addition to HPLC to determine the stability of the composition.
- testing using zone of inhibition assays, cell proliferation assays (e.g., using colorimetric dyes), and other equivalent methods are also encompassed by the present invention.
- FIG. 1A-D depict embodiments of the present invention. These formulations can be prepared by using the following exemplary methods.
- the formulation depicted in FIG. 1A can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C.
- amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (63FP), and colloidal silicon dioxide are weighed into the amounts listed in FIG. 1A and then mixed in a container, such as, a glass bottle to form a dry blend.
- a container such as, a glass bottle to form a dry blend.
- the oil suspension is then added to the container.
- the container is shaken to suspend the dry blend in the oil suspension.
- the formulation depicted in FIG. 1B can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C.
- amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (244FP), and colloidal silicon dioxide are weighed into the amounts listed in FIG. 1B and then mixed in a container, such as, a glass bottle to form a dry blend.
- a container such as, a glass bottle to form a dry blend.
- the oil suspension is then added to the container.
- the container is shaken to suspend the dry blend in the oil suspension.
- the formulation depicted in FIG. 1C can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C.
- amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (72FP), and colloidal silicon dioxide are weighed into the amounts listed in FIG. 1C and then mixed in a container, such as, a glass bottle to form a dry blend.
- a container such as, a glass bottle to form a dry blend.
- the oil suspension is then added to the container.
- the container is shaken to suspend the dry blend in the oil suspension.
- the formulation depicted in FIG. 1D can be prepared by adding sorbitan monostearate, BHA, and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C.
- amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (63FP), and colloidal silicon dioxide are weighed into the amounts listed in FIG. 1D and then mixed in a container, such as, a glass bottle to form a dry blend.
- a container such as, a glass bottle to form a dry blend.
- the oil suspension is then added to the container.
- the container is shaken to suspend the dry blend in the oil suspension.
- Reconstituted suspensions of the present invention as listed in FIG. 1A-C and prepared according to Example 2, can be tested for stability at a temperature of about 20° C. to about 25° C. and compared to the brand product (Augmentin®) which is stored at about 4° C.
- the following data represents the observed results of this stability test.
- FIG. 1A FIG. 1 C Fig. 1B Augmentin ® 0 Off-white to Off-white to Off-white to Cream colored cream colored cream colored viscous suspension, settles suspension, settles suspension, settles suspension. quickly less quickly than less quickly than the formulation in the formulation in FIG. 1A
- FIG. 1C 1 Off-white to Off-white to Off-white to Cream colored cream colored cream colored viscous suspension, settles suspension, settles suspension, settles suspension, settles suspension. quickly less quickly than less quickly than the formulation in the formulation in FIG. 1A
- FIG. 1C 5 Yellow colored Yellow colored Yellow colored Cream colored suspension, settles suspension, settles suspension, settles viscous quickly less quickly than less quickly than suspension. the formulation in the formulation in FIG. 1A FIG. 1C
- the formulations described in FIG. 1A-C can be tested to determine the degradation of clavulanic acid and amoxicillin. These formulations can be prepared as described in Example 2 and then stored at a temperature of about 20° C. to about 25° C.
- the brand product (Augmentin®) can be prepared according to its labeling instructions and stored at a temperature of about 4° C. as the product labeling recommends.
- FIG. 1A 125.3 108.6 98.3 107.7 107.3 105.3 104.2 101.9 Bottom Sample 2- FIG. 1A 101.5 106.7 99.5 95.9 99.6 108.0 105.3 97.3 Top 72FP Sample 3- FIG. 1C 215.3 99.2 99.7 94.9 165.2 100.0 107.1 98.8 Bottom Sample 4- FIG. 1C 104.0 103.0 93.4 92.3 100.0 104.6 101.2 97.1 Top 244FP Sample 5- FIG.
- FIG. 1B 108.0 106.0 103.5 93.6 98.9 99.6 110.4 98.8 Bottom Sample 6- FIG. 1B 106.0 105.7 100.3 94.4 99.6 103.3 107.1 99.0 Top NA Augmentin ®- N/A 112.5 113.4 103.3 97.7 101.0 111.0 104.3 98.1 1Bottom NA Augmentin ®- N/A 115.7 112.9 103.2 97.5 103.0 110.0 104.6 98.5 2 Top
- the sample containing 244FP (the formulation shown in FIG. 1B ) had approximately 13% clavulanic acid degradation after 8 days at a temperature of about 20° C. to about 25° C.
- the brand product had approximately 15% clavulanic acid degradation after 8 days despite being stored at 4° C.
- the inventors have also tested the formulation stability of formulations of the present invention which use pre-dried powdered excipients.
- part of the powdered components in the test formulation including silicon dioxide, colloidal silicon dioxide and magnesium tricilicate, were dried in 105° C. oven overnight to reduce their water content.
- the samples (powders) of these materials from the same containers without drying were also studied.
- MCT medium chain triglyceride
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
Description
- The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
- β-Lactam antibiotics are commonly prescribed antibiotics that are active against both gram-positive and gram-negative organisms. See Goodman and Gilman's, The Pharmacological Basis of Therapeutics, Ninth Ed., 1996 (Goodman and Gilman's). Penicillins include penicillins G and V which are active against gram-positive cocci, naficillin which is active against penicillinase-producing Staphylococcus aureus and ampicillin which has an improved gram-negative spectrum of activity. Unfortunately, bacterial resistance to β-lactam antibiotics is growing. A major mechanism of resistance involves the production of β-lactamases by the bacteria. β-lactamases cleave the β-lactam ring generating penicilloic acid, which is not bacteriocidal.
- β-lactamases can be inhibited by molecules which bind to the β-lactamases, acting as competitive substrates for the enzymes. One such molecule, clavulanic acid, binds irreversibly to the β-lactamases, irreversibly inhibiting the enzyme. Clinically, the addition of β-lactamase inhibitors to penicillins is very important because it extends the spectrum of bacteriocidal activity. For example, the combination of amoxicillin and clavulanic acid is effective against the β-lactamase-producing strains of staphylococci, H. influenza, gonococci and E. coli. The addition of clavulanic acid to ticarcillin extends its bacteriocidal activity to include aerobic gram-negative bacilli, Staphylococcus aureus as well as Bacteroides species. Other β-lactamases inhibitors include, sulbactam and tazobactam.
- Unfortunately, β-lactamase inhibitors such as clavulanic acid are unstable in aqueous media. U.S. Pat. No. 6,177,421. Clavulanic acid is susceptible to hydrolytic degradation. There exists a narrow range of pH and temperature where the molecule is most stable. Wildfeuer et al. Arzneimittelforschung 41(1):70-73 (1991).
- Given the growth of antibiotic resistant bacteria and the importance of penicillins as a first-line therapy, there exists a continuing need to develop formulations containing β-lactamase inhibitors that are stable.
- The present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). In some embodiments, the antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a carbapenem, and mixtures thereof. In some embodiments, the antibiotic is a penicillin selected from the group consisting of penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloacllin, ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, meziocillin, aziocillin, and mixtures thereof.
- The triglycerides can be selected from the group consisting of short chain triglycerides, medium chain triglycerides, and long chain triglycerides. In some embodiments, the triglycerides are medium chain triglycerides.
- In some embodiments, the triglycerides can be about 5% (w/v) to about 99% (w/v), about 25% (w/v) to about 99% (w/v), about 50% (w/v) to about 99% (w/v), about 75% (w/v) to about 99% (w/v), about 85% (w/v) to about 99% (w/v), or about 95% (w/v) to about 99% (w/v) of the composition.
- In some embodiments, the composition has less than about 1% water (w/v), in another embodiment there is less than about 0.5% water (w/v), and in a third embodiment there is less than about 0.1% water (w/v). The composition can also be a dry triglyceride liquid formulation in some embodiments.
- The composition of the present invention can further comprise a β-lactamase inhibitor, for example, clavulanic acid. In some embodiments, the compositions of the present invention comprise clavulanic acid, amoxicillin, and medium chain triglycerides.
- The present invention is further directed to a composition comprising a penicillin and a β-lactamase inhibitor in a liquid comprising medium chain triglycerides, wherein the concentration of triglycerides ranges from about 5% (w/v) to about 95% (w/v), and wherein the composition has less than about 5% water (w/v). In some embodiments, the penicillin is amoxicillin and the β-lactamase inhibitor is clavulanic acid. In some embodiments, the concentration of amoxicillin ranges from about 50 mg/5 ml to about 800 mg/5 ml and clavulanic acid ranges from about 10 mg/5 ml to about 80 mg/5 ml.
- The present invention is also directed to a composition comprising a penicillin and a β-lactamase inhibitor, wherein the penicillin and β-lactamase inhibitor are in a liquid comprising medium chain triglycerides, wherein the concentration of triglycerides can be about 70% (w/v) to about 99% (w/v).
- In some embodiments, the penicillin or antibiotic is stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C.
- The present invention is also directed to kits comprising any embodiment of the compositions of the present invention. For example, the present invention is directed to a kit comprising a composition comprising an antibiotic which can be mixed with a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). In some embodiments, the kit comprises (a) a first container comprising a therapeutically effective amount of an antibiotic and (b) a second container comprising a pharmaceutically acceptable carrier, excipient, diluent or combination thereof. In some embodiments, at least one container can be made of high density polyethylene.
- The present invention is also directed to methods of using the compositions of the present invention. For example, the present invention is directed to a method of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v) to the mammal in need thereof.
-
FIG. 1 (A, B, C, and D) illustrates exemplary embodiments of the present invention. - The headings below are provided solely for organizational purposes and are not intended to impart any division or meaning to this document, unless specifically indicated.
- The present invention is directed to compositions comprising an antibiotic compound in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). In some embodiments, the composition can further comprise a β-lactamase inhibitor. The antibiotic compound can be in suspension or in solution in the liquid comprising triglycerides.
- The term “antibiotic” encompasses any pharmaceutically acceptable compound that can inhibit the growth of or destroy bacteria and/or other microbes, regardless of whether the compound is produced in a microorganism or produced synthetically. This term encompasses disinfectants, antiseptics, and any other antimicrobial compounds. For example, the term “antibiotic” encompasses penicillin and all its derivatives.
- Suitable antibiotics for use in the present invention include, but are not limited to, the β-lactam class of antibiotics which comprises penicillins, cephalosporins, and carbapenems. β-lactam antibiotics are useful as antimicrobial agents. These compounds inhibit the synthesis of the bacterial peptidoglycan cell wall and are active against both gram-positive and gram-negative cell walls.
- Penicillins can be generally classified based on their spectrum of microbial activity. Penicillin G and penicillin V are highly active against strains of gram-positive cocci. However, these drugs are readily hydrolyzed by penicillinase making them ineffective against most strains of Staphylococcus aureus. In some embodiments, the antibiotic of the present invention is penicillin G, penicillin V, or a mixture thereof.
- Penicillinase-resistant penicillins tend to have less potent antimicrobial activity against microbes sensitive to penicillin G but these penicillins are active against Staphylococcus aureus. Exemplary penicillinase-resistant penicillins include, but are not limited to, methicillin, nafcillin, oxacillin, cloxacillin, and dicloxacillin. In some embodiments, the antibiotic of the present invention is methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, or a mixture thereof.
- Another group of penicillins include those whose spectrum of antimicrobial activity extends to include gram-negative organisms such as Haemophilus influenza, E. coli, and Proteus mirabilis. However, these drugs are hydrolyzed by β-lactamases that are found in increasing numbers of gram-negative bacteria. In some embodiments, the antibiotic of the present invention is ampicillin, amoxicillin, bacampicillin, or a mixture thereof.
- Still other penicillins, such as, carbenicillin, carbenicillin indanyl, and ticarcillin are classified together because their spectrum of antimicrobial activity includes Pseudomonas, Enterobacter, and Proteus species. Other extended-spectrum penicillins include mezlocillin and piperacillin, which have activity against Pseudomonas, Klebsiella, and other gram-negative microbes. However, these drugs are also hydrolyzed by β-lactamases. In some embodiments, the antibiotic of the present invention is carbenicillin, carbenicillin indanyl, ticarcillin, mezlocillin, piperacillin, or a mixture thereof.
- The present invention is also directed to using cephalosporins. Cephalosporins can be categorized depending on their generation, as described in Goodman and Gilman's. First generation cephalosporins include cephalothin, cefazolin, cephalexin, and cefadroxil. Second generation cephalosporins include cefamandole, cefoxitin, cefaclor, cefuroxime, cefuroxime axetil, loracarbef, cefonicid, cefotetan, and ceforamide. Third generation cephalosporins include cefoxatime, cefopodoxime proxetil, cefizoxime, cefoperazone, and ceftazidime. Finally, an exemplary fourth generation cephalosporin is cefepime.
- In some embodiments, the antibiotic of the present invention is cephalothin, cefazolin, cephalexin, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefuroxime axetil, loracarbef, cefonicid, cefotetan, ceforamide, cefoxatime, cefopodoxime proxetil, cefizoxime, cefoperazone, ceftazidime, cefepime, or a mixture thereof.
- The present invention is further directed to using β-lactam antibiotics other than penicillins or cephalosporins. These other β-lactam antibiotics include those compounds that have a β-lactam structure but are not considered a penicillin or cephalosporin. For example, the carbapenems which include imipenem, meropenem, and aztreonam. In some embodiments, the antibiotic of the present invention is imipenem, meropenem, aztreonam, or a mixture thereof. As one of skill in the art will appreciate, the above list of antibiotics is not exhaustive and other antibiotics which are not mentioned are also encompassed within the present invention.
- In some embodiments, the compositions of the present invention can comprise more than one antibiotic. For example, the present invention is also directed to a composition comprising more than one antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). In some embodiments, the present invention comprises 2, 3, 4, or 5 or more antibiotics in combination. The antibiotics used in the embodiments of the present invention that comprise more than one antibiotic can be selected from a group consisting of, but not limited to, a penicillin, a cephalosporin, a carbapenem, or a mixture thereof.
- The embodiments of the present invention that include more than one antibiotic can be useful for treating mammals with an infection from more than one bacteria or other microbe. For example, a physician may prescribe a penicillin such as carbenicillin to treat an infection caused by Pseudomonas and a second antibiotic to treat an infection caused by a different microbe that carbenicillin cannot treat.
- The above β-lactam antibiotics are susceptible to inactivation by β-lactamase. The β-lactamase enzyme opens the β-lactam ring in penicillin or other β-lactam antibiotics. This change produces penicillonic acid (from penicillins) and eliminates the antibiotic properties of penicillin. Similar attacks reduce the ability of other β-lactam antibiotics to treat microbe caused diseases. See Despande et. al, Degradation of β-lactam Antibiotics, Current Science, 87:12 1684-1695 (2004).
- This presents a problem for treating those bacteria and other microbes that have the ability to produce β-lactamase as a defense mechanism. For example, if a physician administers a β-lactam antibiotic to treat microbes that produce β-lactamase, the therapeutic effect of the antibiotic with be reduced or there will be no effect.
- To overcome this problem, the antibiotic can be administered in combination with a β-lactamase inhibitor. A “β-lactamase inhibitor” is a compound that can bind β-lactamase thereby preventing it from inactivating the antibiotic. As one of skill in the art will appreciate, this term encompasses all forms of the compound including, for example, acids, bases, salts, and esters thereof, as well as polymorph crystal forms. In some embodiments, a “β-lactamase inhibitor” refers to a pharmaceutically acceptable salts selected from, but not limited to, alkali metal salts such as sodium or potassium, alkaline earth salts or an ammonium salt (all of which are herein referred to as a pharmaceutically acceptable salts).
- In some embodiments, the compositions of the present invention further comprise a β-lactamase inhibitor. The β-lactamase inhibitor can be clavulanic acid, sulbactam, tazobactam, or mixtures thereof, as well as the salts and esters of these compounds. In some embodiments, the β-lactamase inhibitor is potassium clavulanate.
- These β-lactamase inhibitors are often prescribed in association with amino- and ureidopenicillins for treating gram-negative infections. See Naas et al., Integration of a Transposon TnI-Encoded Inhibitor-Resistant β-Lactamase Gene, blaTEM-67 from Proteus mirabilis, into the Escherichia coli Chromosome, Antimicrobial Agents and Chemotherapy, 47:1 p. 19-26, (2003). For example, clavulanic acid has been combined with amoxicillin to form an oral preparation (AUGMENTIN®, available from GlaxoSmithKline, Research Triangle Park, N.C.) and with tiarcillin as a parenteral preparation (TIMENTIN®, available from GlaxoSmithKline, Research Triangle Park, N.C.).
- These products suffer from poor stability because of the water content of their formulations. This is a major problem for clavulanic acid and its salts because they are extremely sensitive to the presence of water and undergo rapid hydrolytic degradation, both as a dry-powder and in a reconstituted state. In particular, in aqueous solutions, clavulanic acid is unstable and beaks down reducing the amount available to bind β-lactamases.
- For example, when amoxicillin and clavulanic acid are used together, the mixture can be reconstituted in water before it is administered to a patient. Even when stored at 4° C., the clavulanic acid degrades rapidly, reducing its effectiveness.
- In some embodiments, the compositions of the present invention comprise less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% water (w/v). The present invention can also comprise less than 5%, 4%, 3%, 2%, 1%, 0.1%, 0.01% (w/v) or be completely free of water. These low water embodiments can be used with water labile components, for example, clavulanic acid.
- According to the present invention, surprisingly, the addition of triglycerides to a liquid suspension containing an antibiotic, e.g. a β-lactam, and a β-lactamase inhibitor, e.g. clavulanic acid, prevents degradation of the clavulanic acid.
- Triglycerides (also known as triacylglycerol or triacylglyceride) are glycerides in which the glycerol is esterified with three fatty acids. Triglycerides are the main constituent of vegetable oil and animal fats. The general chemical structure of triglycerides is shown below:
- R′, R″, and R′″ are alkyl chains (C1-Cn).
- Chain lengths of the fatty acids in naturally occurring triglycerides may range from 3 to 24 carbon atoms, but lengths of 16 and 18 carbon atoms are most common. Shorter chain lengths may be found in some substances (butyric acid in butter). Most naturally occurring fats contain a complex mixture of individual triglycerides. Based on their chain length, triglycerides can be divided into three categories: (i) short chain triglycerides (SCT); (ii) medium chain triglycerides (MCT); and (iii) long chain triglycerides (LCT).
- Short chain triglycerides are triglycerides having short chain fatty acids, e.g., C2-C6. For example, one short chain triglyceride is glyceryl tributyrate.
- Medium chain triglycerides have fatty acids ranging from about C8 to about C10. Some exemplary commercially available medium chain triglycerides are LABRAFAC® (available from Gattefossé Pharma, Saint-Priest Cedex, France) CAPTEX® (available from Parchem, White Plains, N.Y.), NESATOL® (available from Kreglinger Europe, Antwerp, Belgium) WAGLINOL® (available from Industrial Quimica Lasem, S. A., Barcelona, Spain), BERGABEST® (available from Sternchemie, Hamburg, Germany), MIGLYOL® (available from Universal Preserv-A-Chem, Inc., Edison, N.J.), NEOBEE® (available from Stepan Company, Northfield, Ill.), and CRODAMOL® (available from Croda, Edison, N.J.).
- Triglycerides longer than a medium chain triglyceride, e.g. C11 to Cx are called long chain triglycerides. One exemplary long chain triglyceride is castor oil.
- The compositions of the present invention can comprise a short chain, medium chain, or long chain triglyceride. In some embodiments, the triglyceride is a medium chain triglyceride. In some embodiments of the present invention, the use of a medium chain triglyceride can increase the bioavailability of a drug. See Ueda et al., Effect of Ethyl Cellulose in a Medium-Chain Triglyceride on the Bioavailability of Ceftizoxime, J Pharm Sci. 72(4):454-8 (1983).
- The present invention can also comprise a mixture of triglycerides. In some embodiments, the mixture of triglycerides comprises a mixture of a short chain and a medium chain, a short chain and a long chain, or a medium chain and a long chain. Further, the mixture of triglycerides can comprise more than one short chain, more than one medium chain, or more than one long chain.
- The compositions of the present invention can comprise about 1% to about 99% triglycerides (w/v). In some embodiments, the inactive components of the present invention comprise about 1% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to about 100% triglycerides (w/v). In some embodiments, the composition comprises about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of triglycerides (w/v). The term “about” refers to plus or minus 10% of the indicated number. For example, “about 10%” indicates a range of 9% to 11%.
- In some embodiments, the triglycerides are selected from the group consisting of, but not limited to, vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, synthetic triglycerides, modified triglycerides, fractionated triglycerides, medium and long-chain triglycerides, structured triglycerides, and mixtures thereof.
- In some embodiments, the triglycerides can be almond oil; babassu oil; borage oil; blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil; evening primrose oil; grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil; sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate; and glyceryl tricaprylate/caprate/stearate.
- In addition to triglycerides, the compositions of the present invention can further comprise stabilizing agents. A “stabilizing agent” is a compound that can prevent or slow the degradation of the antibiotic or β-lactamase inhibitor while in storage.
- In some embodiments, the compositions of the present invention are stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C. In some embodiments, the compositions of the present invention are stable for about ten days to about 31 days when stored at a temperature of about 20° C. to about 25° C.
- That is, the compositions of the present invention are stable at a temperature of about 20° C. to about 25° C. during a course of antibiotic treatment. In some embodiments, the compositions of the present invention do not require refrigeration during a course of antibiotic treatment. A course of antibiotic treatment can be, but is not limited to, about 1, about 3, about 5, about 7, about 10 days, or about 31 days. Further a course of antibiotic treatment can be as long as the antibiotics are prescribed for use by a medical professional authorized to prescribe antibiotics. This can length can be determined based on the needs and characteristics of the individual patient. For example, if the patient is immunosuppressed or immunocompromised then the course of antibiotic treatment can be longer than a week, a month, or a year, depending on the patient's condition.
- The present invention can further comprise a pharmaceutically acceptable excipient other than the triglycerides previously mentioned. An “excipient” refers to a substance that is used in the formulation of pharmaceutical compositions, and, by itself, generally has little or no therapeutic value. Various excipients can be used in the invention, including those described in Remington: The Science and Practice of Pharmacy, 21st Ed. (2006). Excipients include, but are not limited to, antioxidants, anti-bacterial agents that prevent the decay of the formulation itself as opposed to those exhibiting a therapeutic effect, preservatives, chelating agents, buffering agents, agents for adjusting toxicity, colorings, flavorings and diluting agents, emulsifying and suspending agents, and other substances with pharmaceutical applications.
- The term “pharmaceutically acceptable” excipient refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio. In some embodiments, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized international pharmacopoeia for use in animals, and more particularly in humans. In some embodiments, the excipients used in the compositions of the present invention are pharmaceutically acceptable.
- In some embodiments, at least one of the excipients included in the liquid formulation can be further dried to reduce its moisture content. In some embodiments, the formulation uses dried silicon dioxide, colloidal silicon dioxide, magnesium trisilicate, or combinations of these excipients. The drying can be done using any method known to one of skill in the art, for example, by placing the excipient in a 105° C. oven overnight.
- The dried excipients can be combined with low moisture content medium chain triglycerides (e.g., a moisture content of about 0.0275% w/w). For example, dried silicon dioxide, dried colloidal silicon dioxide and dried magnesium trisilicate and low moisture medium chain triglyceride oil (e.g. 0.0275%, w/w) can be used as part of a low moisture liquid formulation suitable for delivering an active ingredient, such as an antibiotic.
- Some embodiments of the present invention are directed to dry or dehydrated triglyceride liquid formulations comprising an antibiotic. The terms “dry triglyceride liquid formulations” or “dehydrated triglyceride liquid formulations” both refer to pharmaceutical formulations comprising a triglyceride that are substantially free, and in some cases totally free, of water, and can be considered to be dehydrated. These formulations can also be considered anhydrous. Such formulations can be prepared using low moisture content medium chain triglycerides and powdered excipients with low moisture contents. The powdered excipients can be further dried to reduce their moisture content. As is evident, the term “dry” is used in relation to a liquid to mean that the liquid and its contents have a low or a reduced water content. This use of the term “dry” is not intended to mean the liquid is devoid of fluid-like characteristics, e.g., it has become a powder.
- The dry triglyceride liquid formulations of present invention are particularly useful in preventing hydrolytic degradation of clauvanic acid and/or potassium clauvanate when they are in a reconstituted antibiotic formulation. While not wishing to be bound to a single theory, the drying or desiccation of the excipients is believed to maximize their hygroscopic behavior in the reconstituted formulation. For example, silicon dioxide is very hygroscopic and adsorbs large quantities of water up to 30% (w/w) with a relative humidity of around 80% (w/w). This adsorbtive ability is impaired if the silicon dioxide is exposed to humidity or other water before it becomes part of the reconstituted formulation. However, in its dried form, it is believed to adsorb water from within the formulation, which reduces the hydrolytic degradation of clauvanic acid and/or potassium clauvanate when they are in a reconstituted antibiotic formulation.
- The compositions of the present invention can be administered to any mammal in need of the composition that can experience the beneficial effects of the compounds of the invention. Such mammals include humans and non-humans, such as pets and farm animals. Accordingly, the present invention is directed to methods of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v), to the mammal in need thereof.
- Various patients can find utility in the present invention. In some embodiments, the patient is a child. In some embodiments, the patient is about 55 years of age or older. In some embodiments, the patient has a bacterial infection. In some embodiments, the patient has a condition that compromises their immune system, e.g., AIDS or advanced stage cancer.
- The dosage of the antibiotic administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, the frequency of treatment, and the nature of the effect desired. The compositions of the present invention can contain a quantity of a compound(s) according to this invention in an amount effective to treat the condition, disorder or disease of the subject being treated. One of ordinary skill in the art will appreciate that a method of administering pharmaceutically effective amounts of the antibiotic to a patient in need thereof can be determined empirically, or by standards currently recognized in the medical arts. It will be understood that, when administered to, for example, a human patient, the total daily dosage of the agents of the compositions of the present invention will be decided within the scope of sound medical judgment by the attending physician.
- The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, gender and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the agents at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.
- In some embodiments, the compositions of the present invention can be administered in combination with another therapeutic agent. Accordingly, the compositions of the present invention can also include one or more additional therapeutic agents such as, but not limited to, hydrophilic drugs, hydrophobic drugs, hydrophilic macromolecules, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, antibodies, vaccines, nucleosides, nucleotides, nucleoside analogs, genetic materials and/or combinations thereof.
- Additional examples of therapeutic agents that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, other antineoplastic agents, analgesics and anti-inflammatory agents, anti-anginal agents, antihelmintics, anti-arrythmic agents, anti-arthritic agents, anti-asthma agents, anti-viral agents, anti-coagulants, anti-depressants, antidiabetic agents, anti-epileptic agents, anti-emetics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarial agents, antimigraine agents, anti-muscarinic agents, anti-Parkinson's agents, anti-protozoal agents, anti-thyroid agents, thyroid therapeutic agents, anti-tussives, anxiolytic agents, hypnotic agents, neuroleptic agents, beta-blockers, cardiac inotropic agents, corticosteroids, diuretics, gastrointestinal agents, histamine H2-receptors antagonists, immunosuppressants, keratolytics, lipid regulating agents, muscle relaxants, nutritional agents, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, sedatives, sex hormones, sex hormone antagonists or agonists, stimulants antibodies, vaccines, nucleosides, nucleoside analogs and genetic materials. Amphiphilic therapeutic agents and nutritional agents can also be included.
- The terms “treat” and “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or obtain beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of extent of condition, disorder or disease; stabilization (i.e., not worsening) of the state of condition, disorder or disease; delay in onset or slowing of condition, disorder or disease progression; amelioration of the condition, disorder or disease state, remission (whether partial or total), whether detectable or undetectable; or enhancement or improvement of condition, disorder or disease. Treatment includes eliciting a clinically significant response, without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. In some embodiments, the present invention is directed to a method of treating a microbial infection in a mammal, the method comprising administering a composition comprising an antibiotic in a liquid comprising triglycerides, to the mammal in need thereof.
- A “pharmaceutically effective amount” means an amount effective to provide a therapeutic effect during a period of treatment. The effect can be the treatment of a bacterial infection or other microbe-caused disease state or condition. In some embodiments, the present infection is directed to a pharmaceutically effective amount of an antibiotic is administered to a mammal in need thereof.
- As discussed previously, the methods and compositions of the present invention can be used to treat microbial caused diseases. In some embodiments, the methods and compositions of the present invention can be used to treat otitis media. Otitis media is an infection or inflammation of the middle ear caused by viral or bacterial infections. It is estimated that 75% of children experience at least one episode of otitis media by their third birthday, however, this infection is not limited to children. Otitis media can be treated using antibiotics. See Berman et al., Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population, Pediatrics, 102(1 Pt 1):157 (1998); Glasziou et al., Antibiotics for acute otitis media in children, Cochr ane Database Syst Rev. (2):CD000219 (2000). Thus, in some embodiments, the compositions of the present invention can be administered to a patient with otitis media to treat the infection.
- The present invention is also directed to kits comprising a composition of the present invention. In some embodiments, the kits of the present invention further comprise a container or other means for holding the compositions of the present invention. In some embodiments, there is one container, two containers, three containers, or more than three containers.
- Traditional aqueous based antibiotic formulations can be prepared at the pharmacy by mixing a measured amount of the powdered components with water. These formulations require refrigeration after mixing.
- The kits of the present invention can be used to prepare the pharmaceutical compositions in a manner distinct from traditional kits. The medium chain triglycerides can be in a container separate from the powdered components, which can be in their own distinct container. The powdered components can comprise an antibiotic and clavulanic acid, or another β-lactamase inhibitor, either together or in separate containers. This allows the pharmacist to either pour the powders into the container with the liquid or vice versa. Storing the liquid and powder components in separate containers within a kit helps keep all the formulary components moisture-free because each container is only opened at the time of reconstitution, limiting the exposure to moisture in the environment.
- Thus, in some embodiments, the kit comprises (a) a first container or other means for containing a therapeutically effective amount of the composition of the present invention and (b) a second container or other means for containing a pharmaceutically acceptable carrier, excipient, diluent or combination thereof. For example, the powdered portion of the formulation is stored in one container while the liquid is stored in a separate container. Optionally, the kit can have additional containers or other means for containing comprising a therapeutically effective amount of additional agents or excipients.
- In some embodiments, the kit comprises a container or other means for containing for the separate compositions, such as, a divided bottle or a divided foil packet, however, the separate compositions can also be contained within a single, undivided container. Typically, the kit contains directions for administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
- In some embodiments, the antibiotic is in one container or other means for containing and the triglycerides are in another. The physician or pharmacist can then mix the two components to form a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). Any powdered excipients desired for the formulation can be present with the triglycerides (e.g., in a solution or a suspension) or they can be in a mixture with the antibiotic. The β-lactamase inhibitor may be in a container with the antibiotic or separate from the antibiotic in another container with powder.
- In some embodiments, the kit of the present invention can further comprise an additional container or means for containing comprising a therapeutically effective amount of an agent selected from the group consisting of hydrophilic drugs, hydrophobic drugs, hydrophilic macromolecules, cytokines, peptidomimetics, peptides, proteins, toxoids, sera, antibodies, vaccines, nucleosides, nucleotides, nucleoside and/or nucleotide analogs, genetic materials and combinations thereof.
- In some embodiments, the container or other means for containing of the kit is a bottle. This bottle can be moisture-proof, including a moisture proof cap. It is also important to select a bottle that will not be permeable to the triglycerides of the present invention, in particular, to the medium chain triglycerides. Some polymers that are suitable for aqueous solutions would not be suitable for use in the kits of the present invention.
- Suitable containers or other means for containing include, but are not limited to, bottles made of high density polyethylene (HDPE), polypropylene (PP), glass, and metal. HDPE bottles are particularly suited for the present invention because molecules of HDPE have fewer branches and side chains which leads to higher density and smaller pores. This makes it an effective barrier to contain medium chain triglycerides within the bottle as well as an effective barrier to prevent an influx of water. Accordingly, in some embodiments, the container is a HDPE bottle.
- As one of skill in the art will appreciate, the container is not limited to HDPE bottles. Table 1 shows a comparison of the properties of some more bottles contemplated for use in the present invention.
-
TABLE 1 Bottle PET PETG HDPE LDPE PP Moisture Fair to Fair to Good to Good Good to barrier Good Good Excellent Excellent Oxygen Good Good Poor Poor Poor barrier Clarity Clear Clear Opaque Opaque Translucent - A method according to the present invention comprises preparing a pharmaceutical composition by combining a dehydrated triglyceride with a powdered antibiotic and, optionally, a β-lactamase inhibitor such as clavulanic acid. Any of the kits of the present invention are useful in this method.
- The following examples are further illustrative of the present invention, but are not to be construed to limit the scope of the present invention.
- The compositions of the present invention have better stability than aqueous solutions containing clavulanic acid. To demonstrate this, samples of some embodiments of the present invention are prepared at potassium clavulanate concentrations of 15 mg/5 mL, 35 mg/5 mL and 90 mg/5 mL. Each sample is dispersed in a vehicle of medium chain triglycerides and water. Further, the above sample preparation is repeated with the addition of amoxicillin at 250 mg/5 mL. Table 2 shows the ratios of MCT:water that are used in each sample prepared.
-
TABLE 2 Potassium clavulanate MCT:Water 15 mg 35 mg 90 mg (Diluent) (Ratio ~17) (Ratio ~7) (Ratio ~3) 1:3 No amoxicillin No amoxicillin No amoxicillin (pH per USP Amoxicillin Amoxicillin Amoxicillin between 250 mg/5 mL 250 mg/5 mL 250 mg/5 mL 3.8 to 6.6) 1:1 No amoxicillin No amoxicillin No amoxicillin (pH per USP Amoxicillin Amoxicillin Amoxicillin between 250 mg/5 mL 250 mg/5 mL 250 mg/ 5 mL 3.8 to 6.6) 3:1 No amoxicillin No amoxicillin No amoxicillin (pH per USP Amoxicillin Amoxicillin Amoxicillin between 250 mg/5 mL 250 mg/5 mL 250 mg/ 5 mL 3.8 to 6.6) 100% MCT No amoxicillin No amoxicillin No amoxicillin Amoxicillin Amoxicillin Amoxicillin 250 mg/5 mL 250 mg/5 mL 250 mg/ 5 mL - The pH of the samples is controlled so that the mixture of amoxicillin and potassium clavulanate have a pH of about 3.8 to about 6.6. Solutions of pure amoxicillin (2 mg/ml) have an optimum pH range of about 3.8 to about 6.0 and solutions of pure clavulanate potassium (1% solution) have an optimum pH range of about 3.8 to about 8.0.
- These samples are stored at both a temperature of about 20° C. to about 25° C. and under refrigeration (about 4° C.) and are tested for pH and the amount of amoxicillin and clavulanate. The samples to be tested for pH and the amount of amoxicillin and clavulanate at the following time points: 0 day (day of reconstitution), 5 day, 10 day, 15 day, 1 month, 2 months and 3 months after reconstitution.
- The pH is measured using any technique known to one of skill in the art. For example, using the methods described in the U.S. Pharmacopoeia.
- The amount of amoxicillin and clavulanate are measured using HPLC or other assay capable of measuring the amount of amoxicillin and clavulanate. Quantification of the compounds by HPLC is used to determine the unknown concentration of both amoxicillin and clavulanate in the samples. The samples are injected (about 10-20 μl) into a liquid chromatograph equipped with a 210-nm detector and a 4-mm×30-cm column that contains 3- to 10-μm packing L1. See U.S. Pharmacopoeia. The peaks of the sample are compared to the injection of a series of known concentrations of the standard compound solution (e.g., about 10 μl of amoxicillin and/or about 20 μl of clavulanate) onto the HPLC for detection. The chromatograph of these known concentrations gives a series of peaks that correlate to the concentration of the samples that are injected. The chromatogram is recorded and the responses for the major peaks are measured. One of skill in the art can then determine the percentage of clavulanate or amoxicillin in the solution using the methods described in the U.S. Pharmacopoeia or other equivalent method.
- Further, for in vivo studies testing the stability of the samples, high-performance liquid chromatographic methods using ultraviolet detection at 220 nm can be used for the simultaneous determination of amoxicillin and clavulanic acid in human or dog plasma. See Hoizey et al., J Pharm Biomed Anal. 15; 30(3):661-6 (2002); Choi et al., J Pharm Biomed Anal. 1; 35(1):221-31 (2004).
- As one of skill in the art will appreciate, the stability of the composition can be tested using methods other than HPLC. For example, bioassays and spectrophotometric methods could be used in place of HPLC or in addition to HPLC to determine the stability of the composition. Thus, testing using zone of inhibition assays, cell proliferation assays (e.g., using colorimetric dyes), and other equivalent methods are also encompassed by the present invention.
- The formulations in
FIG. 1A-D depict embodiments of the present invention. These formulations can be prepared by using the following exemplary methods. - The formulation depicted in
FIG. 1A can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C. - Next, the amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (63FP), and colloidal silicon dioxide are weighed into the amounts listed in
FIG. 1A and then mixed in a container, such as, a glass bottle to form a dry blend. The oil suspension is then added to the container. The container is shaken to suspend the dry blend in the oil suspension. - The formulation depicted in
FIG. 1B can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C. - Next, the amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (244FP), and colloidal silicon dioxide are weighed into the amounts listed in
FIG. 1B and then mixed in a container, such as, a glass bottle to form a dry blend. The oil suspension is then added to the container. The container is shaken to suspend the dry blend in the oil suspension. - The formulation depicted in
FIG. 1C can be prepared by adding sorbitan monostearate and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C. - Next, the amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (72FP), and colloidal silicon dioxide are weighed into the amounts listed in
FIG. 1C and then mixed in a container, such as, a glass bottle to form a dry blend. The oil suspension is then added to the container. The container is shaken to suspend the dry blend in the oil suspension. - The formulation depicted in
FIG. 1D can be prepared by adding sorbitan monostearate, BHA, and BHT to medium chain triglycerides to form a mixture, heating the mixture to 55° C., and then mixing the mixture until the components have dissolved. The resulting oil suspension is then cooled to a temperature of about 20° C. to about 25° C. - Next, the amoxicillin trihydrate, potassium clavulanate/silicon dioxide blend (1:1 blend), silicon dioxide (63FP), and colloidal silicon dioxide are weighed into the amounts listed in
FIG. 1D and then mixed in a container, such as, a glass bottle to form a dry blend. The oil suspension is then added to the container. The container is shaken to suspend the dry blend in the oil suspension. - Reconstituted suspensions of the present invention, as listed in
FIG. 1A-C and prepared according to Example 2, can be tested for stability at a temperature of about 20° C. to about 25° C. and compared to the brand product (Augmentin®) which is stored at about 4° C. The following data represents the observed results of this stability test. -
TABLE 3 Time point Formulation in Formulation in Formulation in (days) FIG. 1A FIG. 1 C Fig. 1B Augmentin ® 0 Off-white to Off-white to Off-white to Cream colored cream colored cream colored cream colored viscous suspension, settles suspension, settles suspension, settles suspension. quickly less quickly than less quickly than the formulation in the formulation in FIG. 1A FIG. 1C 1 Off-white to Off-white to Off-white to Cream colored cream colored cream colored cream colored viscous suspension, settles suspension, settles suspension, settles suspension. quickly less quickly than less quickly than the formulation in the formulation in FIG. 1A FIG. 1C 5 Yellow colored Yellow colored Yellow colored Cream colored suspension, settles suspension, settles suspension, settles viscous quickly less quickly than less quickly than suspension. the formulation in the formulation in FIG. 1A FIG. 1C - The formulations described in
FIG. 1A-C can be tested to determine the degradation of clavulanic acid and amoxicillin. These formulations can be prepared as described in Example 2 and then stored at a temperature of about 20° C. to about 25° C. The brand product (Augmentin®) can be prepared according to its labeling instructions and stored at a temperature of about 4° C. as the product labeling recommends. - At time points of 0 days (reconstitution of powder), 1 day, 5 days, and 8 days the following results were obtained using the HPLC methods described in the US Pharmacopoeia. Samples are withdrawn for assay from the top and bottom of the bottle to assess the homogeneity of the suspension.
-
TABLE 4 Syloid Type % Clav. % Amoxi. (Silcon Formulation 0 1 5 8 0 1 5 8 Gel) Sample Info in FIG. 1. Day Day Day Day Day Day Day Day 63FP Sample 1- FIG. 1A 125.3 108.6 98.3 107.7 107.3 105.3 104.2 101.9 Bottom Sample 2- FIG. 1A 101.5 106.7 99.5 95.9 99.6 108.0 105.3 97.3 Top 72FP Sample 3- FIG. 1C 215.3 99.2 99.7 94.9 165.2 100.0 107.1 98.8 Bottom Sample 4- FIG. 1C 104.0 103.0 93.4 92.3 100.0 104.6 101.2 97.1 Top 244FP Sample 5- FIG. 1B 108.0 106.0 103.5 93.6 98.9 99.6 110.4 98.8 Bottom Sample 6- FIG. 1B 106.0 105.7 100.3 94.4 99.6 103.3 107.1 99.0 Top NA Augmentin ®- N/A 112.5 113.4 103.3 97.7 101.0 111.0 104.3 98.1 1Bottom NA Augmentin ®- N/A 115.7 112.9 103.2 97.5 103.0 110.0 104.6 98.5 2 Top - As illustrated in Table 4, the sample containing 244FP (the formulation shown in
FIG. 1B ) had approximately 13% clavulanic acid degradation after 8 days at a temperature of about 20° C. to about 25° C. The brand product had approximately 15% clavulanic acid degradation after 8 days despite being stored at 4° C. - The inventors have also tested the formulation stability of formulations of the present invention which use pre-dried powdered excipients. For this test, part of the powdered components in the test formulation, including silicon dioxide, colloidal silicon dioxide and magnesium tricilicate, were dried in 105° C. oven overnight to reduce their water content. As a comparison, the samples (powders) of these materials from the same containers without drying were also studied.
- Various medium chain triglyceride (MCT) oil samples with different moisture levels of 0.0275, 0.05, 0.1 and 0.15% (w/w) were evaluated for determining the stability of the formulation after reconstitution.
- The stability of a formulation (600 mg/42.9 mg) was monitored using color change as an indicator of formulation stability. In general, the whiter the formulation appears, the more stable the formulation. It has been observed that for the formulations without pre-dried powders, the reconstituted suspension of the product became dark yellow on the second day after reconstitution, irrespective of the moisture level of MCT oil.
- However, the formulations using pre-dried powders (silicon dioxide, colloidal silicon dioxide and magnesium trisilicate) did not show any color change for 3 days at all moisture levels of MCT oil after reconstitution. After 3 days following reconstitution, gradual color changes were observed in the formulations containing high moisture level MCT oil, whereas no color change or slight off-white was seen in 0.0275% MCT oil formulations for 21 days kept at room temperature(23±2° C.).
- Similar observations were obtained on 200/28.5 mg formulation. The observation difference was the color change of the 200/28.5 mg formulations was faster than the 600/42.9 mg formulations. This may be attributed to the fact that the 200/28.5 mg formulation has far less amount of dry powders than the 600/42.9 mg formulation.
- These examples illustrate possible embodiments of the present invention. As one of skill in the art will appreciate, because of the versatility of the compositions, kits, and methods of using the compositions disclosed herein, the compositions, kits, and methods can be used in other similar ways to those described herein. Thus, while the invention has been particularly shown and described with reference to some embodiments thereof, it will be understood by those skilled in the art that they have been presented by way of example only, and not limitation, and various changes in form and details can be made therein without departing from the spirit and scope of the invention. Therefore, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
- All documents cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued or foreign patents, or any other documents, are each entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited documents.
Claims (20)
1-25. (canceled)
26. A liquid pharmaceutical composition comprising a β-lactamase inhibitor; one or more of dried silicon dioxide, dried colloidal silicon dioxide and dried magnesium trisilicate; and a low moisture content medium chain triglyceride vehicle, wherein the composition is a liquid, the concentration of medium chain triglycerides ranges from about 50% to about 99% (w/v) of the composition, and the composition contains less than about 1.0% (w/v) water.
27. The composition of claim 26 , wherein the composition is a suspension.
28. The composition of claim 26 , wherein the one or more of silicon dioxide, colloidal silicon dioxide and magnesium trisilicate are dried prior to inclusion in the pharmaceutical composition.
29. The composition of claim 26 , wherein the medium chain triglycerides contain less than about 0.1% (w/w) water.
30. The composition of claim 26 , wherein the composition is suitable for oral delivery.
31. The composition of claim 26 , wherein the β-lactamase inhibitor is selected from the group consisting of clavulanic acid, sulbactam, tazobactam, and mixtures thereof.
32. The composition of claim 26 , wherein the β-lactamase inhibitor is clavulanic acid.
33. The composition of claim 26 , wherein the β-lactamase inhibitor is stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C.
34. A liquid pharmaceutical composition, comprising a β-lactamase inhibitor, one or more dried hygroscopic excipients and a low moisture content medium chain triglyceride vehicle, wherein the composition is a liquid and the composition contains less than about 1.0% (w/v) water.
35. The composition of claim 34 , wherein the composition is a suspension.
36. The composition of claim 34 , wherein the β-lactamase inhibitor is selected from the group consisting of clavulanic acid, sulbactam, tazobactam, and mixtures thereof.
37. The composition of claim 34 , wherein the β-lactamase inhibitor is clavulanic acid.
38. The composition of claim 34 , wherein the one or more hygroscopic excipients comprise one or more of silicon dioxide, colloidal silicon dioxide and magnesium trisilicate.
39. The composition of claim 34 , wherein the hygroscopic excipients are dried prior to inclusion in the pharmaceutical composition.
40. The composition of claim 34 , wherein the medium chain triglycerides contain less than about 0.1% (w/w) water.
41. The composition of claim 34 , wherein the concentration of medium chain triglycerides is from about 50% (w/v) to about 99% (w/v).
42. The composition of claim 34 , wherein the β-lactamase inhibitor is stable for at least about ten days when stored at a temperature of about 20° C. to about 25° C.
43. The composition of claim 34 , wherein the composition is suitable for oral delivery.
44. A liquid pharmaceutical composition for oral delivery consisting essentially of a β-lactamase inhibitor, one or more of silicon dioxide, colloidal silicon dioxide and magnesium trisilicate, and a low moisture content medium chain triglyceride vehicle, wherein the composition is a liquid, the concentration of medium chain triglycerides ranges from about 50% to about 99% (w/v) of the composition, and the composition contains less than about 1.0% (w/v) water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/873,391 US20130237512A1 (en) | 2006-09-26 | 2013-04-30 | Stabilizing compositions for antibiotics and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84709306P | 2006-09-26 | 2006-09-26 | |
US11/902,925 US8106040B2 (en) | 2006-09-26 | 2007-09-26 | Stabilizing compositions for antibiotics and methods of use |
US13/299,829 US8461143B2 (en) | 2006-09-26 | 2011-11-18 | Stabilizing compositions for antibiotics and methods of use |
US13/873,391 US20130237512A1 (en) | 2006-09-26 | 2013-04-30 | Stabilizing compositions for antibiotics and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/299,829 Continuation US8461143B2 (en) | 2006-09-26 | 2011-11-18 | Stabilizing compositions for antibiotics and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130237512A1 true US20130237512A1 (en) | 2013-09-12 |
Family
ID=39230807
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/902,925 Expired - Fee Related US8106040B2 (en) | 2006-09-26 | 2007-09-26 | Stabilizing compositions for antibiotics and methods of use |
US13/299,829 Expired - Fee Related US8461143B2 (en) | 2006-09-26 | 2011-11-18 | Stabilizing compositions for antibiotics and methods of use |
US13/873,391 Abandoned US20130237512A1 (en) | 2006-09-26 | 2013-04-30 | Stabilizing compositions for antibiotics and methods of use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/902,925 Expired - Fee Related US8106040B2 (en) | 2006-09-26 | 2007-09-26 | Stabilizing compositions for antibiotics and methods of use |
US13/299,829 Expired - Fee Related US8461143B2 (en) | 2006-09-26 | 2011-11-18 | Stabilizing compositions for antibiotics and methods of use |
Country Status (5)
Country | Link |
---|---|
US (3) | US8106040B2 (en) |
EP (1) | EP2066302A2 (en) |
CN (2) | CN101516334B (en) |
CA (1) | CA2661576A1 (en) |
WO (1) | WO2008039472A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476447A (en) * | 1968-03-28 | 1969-11-04 | Westinghouse Electric Corp | Self-aligning hydrostatic bearing |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8106040B2 (en) | 2006-09-26 | 2012-01-31 | Taro Pharmaceuticals North America, Inc. | Stabilizing compositions for antibiotics and methods of use |
EP2237684A2 (en) * | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
CN103550214A (en) * | 2008-03-26 | 2014-02-05 | 塔罗制药北美有限公司 | Stabilizing lipid compositions for oral pharmaceutical agents |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US20130164337A1 (en) * | 2010-09-13 | 2013-06-27 | Viktor Lvovich Limonov | Antimicrobial action pharmaceutical composition for parenteral administration and its production process |
GB2529605B (en) * | 2014-06-03 | 2018-03-21 | Essential Pharmaceuticals Ltd | Pharmaceutical composition |
CN109689027A (en) * | 2016-06-29 | 2019-04-26 | 奥德纳米有限公司 | Triglycerides aural preparations and application thereof |
CN106265505B (en) * | 2016-11-11 | 2019-06-25 | 成都乾坤动物药业股份有限公司 | A kind of amoxicillin and clavulanate potassium oil suspension and preparation method thereof |
US11021529B2 (en) | 2017-03-03 | 2021-06-01 | Massachusetts Institute Of Technology | Antimicrobial constructs and uses thereof |
PL244822B1 (en) * | 2021-01-11 | 2024-03-11 | Jezierska Monika Celvet Spolka Cywilna | Non-aqueous pharmaceutical composition in the form of oral suspension, method of its preparation and use |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB654215A (en) * | 1948-01-08 | 1951-06-13 | Lilly Co Eli | Improvements in or relating to suspensions of penicillin salts |
GB767153A (en) * | 1954-08-19 | 1957-01-30 | Bristol Lab Inc | Stable penicillin suspensions for oral therapeutic use |
US3402843A (en) | 1966-07-11 | 1968-09-24 | Phillips Petroleum Co | Bottles with protective cape or cover |
GB1372102A (en) | 1971-10-21 | 1974-10-30 | Anchor Hocking Corp | Protection of glass articles |
US3636194A (en) | 1969-10-23 | 1972-01-18 | Douglas G Parizeau | Composition and method for treating mastitis with therapeutic agents |
CA950831A (en) | 1972-04-25 | 1974-07-09 | Leonard D. Kurtz | Biocidal salts |
US3912100A (en) | 1973-06-21 | 1975-10-14 | Owens Illinois Inc | Coated glass container and method of making same |
US3996355A (en) | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
SE7714312L (en) | 1976-12-17 | 1978-06-18 | Scherico Ltd | ANTIBIOTIC COMPOSITIONS |
US4097132A (en) | 1977-02-18 | 1978-06-27 | Bell & Howell Company | Projector molded chassis |
US4172138A (en) | 1977-03-23 | 1979-10-23 | Rhodes Russell E | Method and composition of matter for the treatment of dry cows for mastitis |
IL58461A0 (en) * | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a clavulanic acid salt |
US4918108A (en) * | 1982-03-16 | 1990-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Method of improving the absorption of injected antibacterial substances |
EP0115001B1 (en) * | 1982-12-28 | 1988-06-15 | Bayer Ag | Stable aminoglycoside-penicillin injection formulation |
US4684643A (en) | 1983-08-22 | 1987-08-04 | Eli Lilly And Company | Pharmaceutical compositions for storage in plastic containers and process therefor |
ZA874989B (en) | 1986-07-11 | 1988-02-24 | Sekisui Plastics | Heat-shrinkable sheet |
JP3309145B2 (en) | 1993-06-02 | 2002-07-29 | 大阪真空工業株式会社 | UV blocking film and UV blocking container |
US5795902A (en) | 1993-09-02 | 1998-08-18 | Pfizer Inc. | 3-substituted 2-oxindole-1 carboxamide pharmaceutical compositions |
JPH0958687A (en) | 1995-08-11 | 1997-03-04 | Fuji Seal Co Ltd | Sake container |
KR20010012402A (en) | 1997-05-09 | 2001-02-15 | 세이지 파마슈티칼스, 인크. | Stable oral pharmaceutical dosage forms |
US7276468B1 (en) | 1998-06-30 | 2007-10-02 | Sandia Corporation | Granulated decontamination formulations |
US6177421B1 (en) * | 1999-05-04 | 2001-01-23 | Fuisz International Ltd. | Amoxicillin and clavulanate composition |
CA2376202C (en) | 1999-06-07 | 2008-11-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel preparation and administration form comprising an acid-labile active compound |
ATE334655T1 (en) * | 1999-08-20 | 2006-08-15 | Glaxosmithkline Lab Sas | PHARMACEUTICAL FORMULATION CONTAINING AMOXICILLIN AND CLAVULANATE |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
US6632783B1 (en) | 2000-05-10 | 2003-10-14 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Liquid detergent package with transparent/translucent bottle labels with UV absorbers |
WO2003033633A1 (en) * | 2001-10-18 | 2003-04-24 | Council Of Scientific And Industrial Research | Cholesterol lowering structured lipids with omega 3 pufa |
MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
DE10224086A1 (en) | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmaceutical preparations for oral use containing ion-exchange resins loaded with active substance and structurally viscous gel formers as thickeners |
US20040202696A1 (en) * | 2003-04-14 | 2004-10-14 | Cts Chemical Industries Ltd. | Administration form for veterinary use |
US20050031696A1 (en) | 2003-04-22 | 2005-02-10 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations of acid-labile active ingredients and process for making same |
US20050181052A1 (en) | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
WO2006002050A1 (en) * | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
GB0519391D0 (en) * | 2005-09-22 | 2005-11-02 | Aion Diagnostics Ltd | Imaging agents |
PT1818057E (en) | 2006-02-09 | 2010-06-18 | Teva Pharma | Stable pharmaceutical formulations of montelukast sodium |
US8106040B2 (en) | 2006-09-26 | 2012-01-31 | Taro Pharmaceuticals North America, Inc. | Stabilizing compositions for antibiotics and methods of use |
-
2007
- 2007-09-26 US US11/902,925 patent/US8106040B2/en not_active Expired - Fee Related
- 2007-09-26 WO PCT/US2007/020721 patent/WO2008039472A2/en active Application Filing
- 2007-09-26 CN CN2007800352066A patent/CN101516334B/en not_active Expired - Fee Related
- 2007-09-26 CN CN2013102217460A patent/CN103349659A/en active Pending
- 2007-09-26 EP EP07861372A patent/EP2066302A2/en not_active Withdrawn
- 2007-09-26 CA CA002661576A patent/CA2661576A1/en not_active Abandoned
-
2011
- 2011-11-18 US US13/299,829 patent/US8461143B2/en not_active Expired - Fee Related
-
2013
- 2013-04-30 US US13/873,391 patent/US20130237512A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008039472A3 (en) | 2008-11-27 |
CA2661576A1 (en) | 2008-04-03 |
CN103349659A (en) | 2013-10-16 |
US20120065182A1 (en) | 2012-03-15 |
WO2008039472A2 (en) | 2008-04-03 |
US8461143B2 (en) | 2013-06-11 |
CN101516334B (en) | 2013-07-10 |
US8106040B2 (en) | 2012-01-31 |
CN101516334A (en) | 2009-08-26 |
US20080076749A1 (en) | 2008-03-27 |
EP2066302A2 (en) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8461143B2 (en) | Stabilizing compositions for antibiotics and methods of use | |
RU2397768C2 (en) | Intended for injection compositions for overcoming beta-lactamase-mediated resistance to antibiotics with application of beta-lactamase inhibitor | |
JP5809750B2 (en) | Pharmaceutical composition comprising β-lactam antibiotic, sulbactam and β-lactamase inhibitor | |
US4338306A (en) | Adjuvant for promoting absorption of pharmacologically active substances through the rectum | |
CN113194943B (en) | Pharmaceutical composition containing cefotaxime sulbactam or cefotaxime tazobactam with stability and antibacterial activity | |
RU2524665C2 (en) | Ceftaroline-including compositions and methods of treatment | |
Bush et al. | Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations | |
EP1861110A1 (en) | Antibiotic combinations for providing total solution to the treatment of infections | |
Reyns et al. | Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs | |
Rusu et al. | The new fifth-generation cephalosporins–a balance between safety and efficacy | |
WO2001045667A2 (en) | Water-soluble powders for oral solution and use thereof | |
US9987257B2 (en) | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same | |
Chin et al. | Use of anti-infective agents during lactation: part 1—Beta-lactam antibiotics, vancomycin, Quinupristin-Dalfopristin, and linezolid | |
RU2424801C1 (en) | Medication for treatment of infectios diseases | |
Vilvanathan | Penicillins, Cephalosporins, and Other b-Lactam Antibiotics | |
WO2024128238A1 (en) | Therapeutic agent for bacterial infection | |
Carpenter et al. | Single-dose pharmacokinetics of piperacillin/tazobactam in Hispaniolan Amazon parrots (Amazona ventralis) | |
Li | Pharmacokinetics/pharmacodynamics of β-lactams alone and in combination with β-lactamase inhibitors against β-lactamase-inducible Pseudomonas aeruginosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TARO PHARMACEUTICALS NORTH AMERICA, INC., CAYMAN I Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GAO, SHEN, MR.;MOROS, DANIEL A., MR.;ASOTRA, SATISH, MR.;SIGNING DATES FROM 20071031 TO 20071104;REEL/FRAME:030338/0532 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |